Lindong Zhang

Dr. Lindong Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
YCYouming Chen
Youming Chen
ZJZuli Jiang
Zuli Jiang
CZChenxing Zhang
Chenxing Zhang
LZLindong Zhang
Lindong Zhang
HCHuanxiang Chen
Huanxiang Chen
JWJunhu Wan
Junhu Wan
RNA 5-methylcytosine (m5C) is an abundant chemical modification in mammalian RNAs and plays crucial roles in regulating vital physiological and pathological processes, especially in cancer. However, the dysregulation of m5C and its underlying mechanisms in non-small cell lung cancer (NSCLC) remain unclear. Here we identified that NSUN2, a key RNA m5C methyltransferase, is highly expressed in NSCLC tumor tissue. We found elevated NSUN2 expression levels strongly correlate with tumor grade and size, predicting poor outcomes for NSCLC patients. Furthermore, RNA-seq and subsequent confirmation studies revealed the antioxidant-promoting transcription factor NRF2 is a target of NSUN2, and depleting NSUN2 decreases the expression of NRF2 and increases the sensitivity of NSCLC cells to ferroptosis activators both in vitro and in vivo. Intriguingly, the methylated-RIP-qPCR assay results indicated that NRF2 mRNA has a higher m5C level when NSUN2 is overexpressed in NSCLC cells but shows no significant changes in the NSUN2 methyltransferase-deficient group. Mechanistically, we confirmed that NSUN2 upregulates the expression of NRF2 by enhancing the stability of NRF2 mRNA through the m5C modification within its 5'UTR region recognized by the specific m5C reader protein YBX1, rather than influencing its translation. In subsequent rescue experiments, we show knocking down NRF2 diminished the proliferation, migration, and ferroptosis tolerance mediated by NSUN2 overexpression. In conclusion, our study unveils a novel regulatory mechanism in which NSUN2 sustains NRF2 expression through an m5C-YBX1-axis, suggesting that targeting NSUN2 and its regulated ferroptosis pathway might offer promising therapeutic strategies for NSCLC patients.

19 December 2023 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
MZMengjun Zhang
Mengjun Zhang
JWJialin Wang
Jialin Wang
YGYan Guo
Yan Guo
HYHaodi Yue
Haodi Yue
LZLindong Zhang
Lindong Zhang
Background: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%. Platinum resistance is the chief culprit for the high recurrence and mortality rates. Several studies confirm that the metabolic regulation of ubiquitinating enzymes plays a vital role in platinum resistance in OC. Methods: In this study, we selected ubiquitin-conjugating enzyme E2S (UBE2S) as the candidate gene for validation. The levels of UBE2S expression were investigated using TCGA, GTEx, UALCAN, and HPA databases. In addition, the correlation between UBE2S and platinum resistance in OC was analyzed using data from TCGA. Cisplatin-resistant OC cell lines were generated and UBE2S was knocked down; the transfection efficiency was verified. Subsequently, the effects of knockdown of UBE2S on the proliferation and migration of cisplatin-resistant OC cells were examined through the CCK8, Ki-67 immunofluorescence, clone formation, wound healing, and transwell assays. In addition, the UBE2S gene was also validated in vivo by xenograft models in nude mice. Finally, the relationship between the UBE2S gene and autophagy and the possible underlying regulatory mechanism was preliminarily investigated through MDC and GFP-LC3-B autophagy detection and western blotting experiments. Most importantly, experimental validation of mTOR agonist reversion (the rescuse experiments) was also performed. Results: UBE2S was highly expressed in OC at both nucleic acid and protein levels. The results of immunohistochemistry showed that the level of UBE2S expression in platinum-resistant samples was significantly higher relative to the platinum-sensitive samples. By cell transfection experiments, knocking down of the UBE2S gene was found to inhibit the proliferation and migration of cisplatin-resistant OC cells. Moreover, the UBE2S gene could inhibit autophagy by activating the PI3K/AKT/mTOR signaling pathway to induce cisplatin resistance in OC in vivo and in vitro. Conclusion: In conclusion, we discovered a novel oncogene, UBE2S, which was associated with platinum response in OC, and examined its key role through bioinformatics and preliminary experiments. The findings may open up a new avenue for the evaluation and treatment of OC patients at high risk of cisplatin resistance.

18 January 2024 in Heliyon
Verified
Journal Article
Open access
MZMengjun Zhang
Mengjun Zhang
JWJialin Wang
Jialin Wang
ZZZidi Zhang
Zidi Zhang
YGYan Guo
Yan Guo
XLXueling Lou
Xueling Lou
LZLindong Zhang
Lindong Zhang
The Ubiquitin Conjugating Enzyme E2 S (UBE2S), was initially identified as a crucial member in controlling substrate ubiquitination during the late promotion of the complex's function. In recent years, UBE2S has emerged as a significant epigenetic modification in various diseases, including myocardial ischemia, viral hepatitis, and notably, cancer. Mounting evidence suggests that UBE2S plays a pivotal role in several human malignancies including breast cancer, lung cancer, hepatocellular carcinoma and etc. However, a comprehensive review of UBE2S in human tumor research remains absent. Therefore, this paper aims to fill this gap. This review provides a comprehensive analysis of the structural characteristics of UBE2S and its potential utility as a biomarker in diverse cancer types. Additionally, the role of UBE2S in conferring resistance to tumor treatment is examined. The findings suggest that UBE2S holds promise as a diagnostic and therapeutic target in multiple malignancies, thereby offering novel avenues for cancer therapy.

30 August 2022 in Frontiers in Genetics
Verified
Journal Article
Open access
MZMengjun Zhang
Mengjun Zhang
JWJialin Wang
Jialin Wang
HYHaodi Yue
Haodi Yue
LZLindong Zhang
Lindong Zhang
Background: Ovarian cancer (OV) is one of the most common gynecological malignancies worldwide, and its immunotherapy has considerable prospects. Multiple members of the CMTM family were aberrantly expressed in human cancers and controlled key malignant biological processes and immune regulation in cancer development. However, little is known about the function of this gene family in ovarian cancer, especially in terms of immunity.Methods: GEPIA, Oncomine, HPA, Kaplan–Meier plotter, cBioPortal, GeneMANIA, and TIMER were used to analyze the differential gene expression, prognostic value, genetic alterations, and alterations in the immune microenvironment of the CMTM family in patients with ovarian cancer. Importantly, RT-qPCR was used to verify the gene expression of the CMTM family.Results: CMTM1/3/4/6/7/8 showed abnormally high expression at the mRNA and protein levels in OV tissues based on the GEPIA and HPA databases. RT-qPCR showed that CMTM1/6/8 was highly expressed in ovarian cancer cell lines. IHC verified that CMTM8 is highly expressed in ovarian cancer tissues and is closely related to Ki-67. Survival analysis showed that high expression of CMTM1/2/3/5/8 can lead to a significant reduction in overall survival and progression-free survival. There were many types of genetic alterations in the CMTM family. Also, CMTM1/2/3/6 had a certain correlation with the changes in the immune microenvironment such as immune cell infiltration and immune checkpoint expression, which may be the potential mechanism of the CMTM family in ovarian cancer. IHC verified that CMTM6 is highly expressed in ovarian cancer tissues and is closely related to PD-L1.Conclusion: This study confirmed that the CMTM family has abnormal expression in ovarian cancer and CMTM8 can be used as a biomarker for prognostic evaluation. Also, the CMTM family may be used as a potential target for immunotherapy based on the suppression of immune checkpoints.

2 January 2026 in Functional & Integrative Genomics
Verified
Journal Article
Closed access
PDF file
MZMengjun Zhang
Mengjun Zhang
JWJialin Wang
Jialin Wang
HYHaodi Yue
Haodi Yue
ZZZidi Zhang
Zidi Zhang
LZLindong Zhang
Lindong Zhang
XZXin Zhao
Xin Zhao

5 May 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
MZMengjun Zhang
Mengjun Zhang
ZZZidi Zhang
Zidi Zhang
JWJialin Wang
Jialin Wang
HYHaodi Yue
Haodi Yue
XLXueling Lou
Xueling Lou
LZLindong Zhang
Lindong Zhang
Endometriosis is a chronic disease that jeopardises the quality of life of about 10% of women. The aim of this study was to investigate the expression, function, regulatory mechanism, and relationship with immune cell infiltration of PNMA2 in endometriosis. This study investigates the potential involvement and regulatory mechanisms of PNMA2 in the development of endometriosis through the integration of public data, machine learning, clinical sample transcriptome sequencing, and in vitro cell experiments. Cytological in vitro experiments were conducted to validate the impact of PNMA2 on the modulation of proliferation, migration, apoptosis, and autophagy in 12z cells. Rescue experiments were performed based on the autophagy activator ( RAPA ) to clarify the regulatory details of PNMA2 , apoptosis, and autophagy. The Ciberort algorithm was employed to discern the association between PNMA2 gene expression and more than 20 distinct immune cell infiltration types in endometriosis. The expression of PNMA2 exhibited a notable increase in individuals with endometriosis. Knockdown of PNMA2 inhibited the proliferation and migration of 12z cells. Knockdown of PNMA2 could directly promote apoptosis and could also inhibit autophagy and indirectly promote apoptosis. PNMA2 displayed associations with immune cell infiltration and immunomodulation. The present study demonstrated that the up‐regulation of PNMA2 was associated with malignant growth, anti‐apoptosis, and immunoregulation of human endometriotic cells. Therefore, PNMA2 may serve as a new diagnostic biomarker and a promising therapeutic target.